Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11069510 | 0.74 | CYP1A2 (0.35) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 | |
| SCHEMBL24698707 | 0.72 | CHRNB2 (0.37) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 | |
| SCHEMBL13882832 | 0.72 | CYP1A2 (0.46) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 | |
| SCHEMBL3201971 | 0.72 | BRD4 (0.39) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 | |
| SCHEMBL1499523 | 0.71 | CYP1A2 (0.42) | ALDH1A1CYP1A2HIF1ABRD4KMT2A | |
| SCHEMBL11065308 | 0.71 | BRD4 (0.34) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 | |
| SCHEMBL11756557 | 0.70 | BRD4 (0.38) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 | |
| SCHEMBL5346726 | 0.69 | CYP1A2 (0.41) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 | |
| SCHEMBL11069436 | 0.69 | CYP1A2 (0.35) | ALDH1A1CYP1A2HIF1ABRD4 | |
| SCHEMBL11055929 | 0.69 | BRD4 (0.33) | ALDH1A1CYP1A2HIF1ABRD4CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038087-B2 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063999-A1 | Process for the production of optically active amino alcohols | ADH1C, ADH1A, ADH5 | ALDH1A1 22/4885CYP1A2 296/4885HIF1A 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.